parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.11 from other evidence	0.00
cell type Human Protein Atlas	cell type enriched in oligodendrocytes (466 nCPM)	1.00
chemistry Open Targets	compounds already reach it: refanezumab	0.81
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	34 Parkinson's papers of 6,020	0.53
pathways Reactome	3 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 2497

receipt 2505: MAG in dopamine neurons, braak

power: full sample +0.16 (p 0.526, n 18), 95% CI -0.33 to +0.58. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.18 (p 0.482, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.12 (p 0.646, n 18). could be the mix.
skeptic: leave-one-out range +0.06 to +0.28, sign flips 0; without severely affected donors +0.16 (p 0.526, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MAG in dopamine neurons.

case closed: nothing better to follow up.

receipt 2504: MAG in oligodendrocytes, braak

power: full sample -0.31 (p 0.204, n 18), 95% CI -0.68 to +0.18. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.29 (p 0.246, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.27 (p 0.285, n 18). could be the mix.
skeptic: leave-one-out range -0.47 to -0.25, sign flips 0; without severely affected donors -0.31 (p 0.204, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MAG in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts